{"id":"licartin-and-cik","safety":{"commonSideEffects":[{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Licartin binds to HAb18G/CD147 antigen expressed on hepatocellular carcinoma cells, facilitating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. CIK cells are ex vivo expanded lymphocytes with both T-cell and NK-cell characteristics that provide adoptive immunotherapy. The combination leverages both targeted monoclonal antibody therapy and cellular immunotherapy mechanisms.","oneSentence":"Licartin is a recombinant human-mouse chimeric monoclonal antibody targeting hepatocellular carcinoma cells, while CIK refers to cytokine-induced killer cells used in adoptive cell immunotherapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:52:09.767Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma"},{"name":"Advanced hepatocellular carcinoma"}]},"trialDetails":[{"nctId":"NCT01758679","phase":"PHASE4","title":"A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2012-01","conditions":"Multiple Drug Use","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Licartin and CIK","genericName":"Licartin and CIK","companyName":"Tianjin Medical University Cancer Institute and Hospital","companyId":"tianjin-medical-university-cancer-institute-and-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"Licartin is a recombinant human-mouse chimeric monoclonal antibody targeting hepatocellular carcinoma cells, while CIK refers to cytokine-induced killer cells used in adoptive cell immunotherapy. Used for Hepatocellular carcinoma, Advanced hepatocellular carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}